For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue from customers | 0 | - | - | 0 |
| Research and development | 321 | 2,280 | 1,120 | 3,702 |
| General and administrative | 3,727 | 4,715 | 5,674 | 3,826 |
| Total operating expenses | 4,048 | 6,995 | 6,794 | 7,528 |
| Loss from operations | -4,048 | -6,995 | -6,794 | -7,528 |
| R&d tax incentive | 82 | 482 | 389 | -432 |
| Foreign exchange losss/(gaines) | 25 | -24 | -13 | 1 |
| Interest income | 6 | - | - | - |
| Change in fair value of warrant liabilities | -380 | - | - | 25,367* |
| Interest income | - | -5 | -5 | -151* |
| Warrant issuance costs | 284 | - | - | -258* |
| Share of earnings (loss) of joint venture | -44 | 11 | 6 | - |
| Interest income | - | - | - | 2 |
| Interest expense | 0 | - | - | - |
| Change in fair value of convertible rights | 0 | - | - | -75* |
| Gain on extinguishment | 0 | - | - | 1,510* |
| Eloc commitment fee | 0 | - | - | -274* |
| Total other income, net | 165 | 474 | 387 | -24,075 |
| Loss before income tax expense | -3,883 | -6,521 | -6,407 | -31,603 |
| Income tax expense | 0 | - | - | - |
| Net loss | -3,883 | -6,521 | -6,407 | -31,603 |
| Currency translation adjustment, net of tax | -468 | -287 | 223 | 371 |
| Total comprehensive loss | -4,351 | -6,808 | -6,184 | -31,232 |
| Basic EPS | -0.35 | -0.02 | -0.02 | -0.377 |
| Diluted EPS | -0.35 | -0.02 | -0.02 | -0.377 |
| Basic Average Shares | 12,348,460 | 349,464,317 | 310,309,659 | 82,917,283 |
| Diluted Average Shares | 12,348,460 | 349,464,317 | 310,309,659 | 82,917,283 |
Incannex Healthcare Inc. (IXHL)
Incannex Healthcare Inc. (IXHL)